Company news

Jiangsu Aidea Pharmaceutical Group Co., Ltd. Class A (SSE:688488) news

Jiangsu Aidea Pharmaceutical Group Co., Ltd. Class A news releases on 6ix. Latest, Sep 18, 2026: "JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD."Announcement…

Jiangsu Aidea Pharmaceutical Group Co., Ltd. Class A (SSE:688488) news

Press releases & updates

"JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD."Announcement on Signing the Supplementary Agreement to Conditional Stock Subscription Contract with a Specific Investor and Related Party Transaction

"JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD."Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry

"JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD."Announcement on Failure to Satisfy Exercise Conditions for the 1st Exercise Period under the 2025 Stock Option Incentive Plan and Cancellation of Certain Stock Options

"JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD."Announcement on Pledge of Certain Shares Held by Persons Acting in Concert with the Actual Controller

"JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD."Announcement on Results of Shareholding Increase by the Actual Controller

"JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD."Announcement on Progress of Acquisition of the Minority Shareholder's Equity Interests in Controlled Subsidiary

"JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD."Announcement on Use of Own Funds, Bank Acceptance Bills and Other Methods to Pay Funds Required for Raised Fund Investment Projects and Equivalent Replacement with Raised Funds

"JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD."Announcement on Cancellation of Certain Dedicated Settlement Accounts for Wealth Management Products Purchased with Raised Funds

"JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD."Announcement on Voluntary Disclosure of Obtaining of Drug Registration Approval for Darunavir Tablets

"JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD."Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial for ADC119 Tablets

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

Announcement on Obtaining Government Subsidies

Announcement on Re-signing Tripartite Supervision Agreement over Deposit in Special Account of Raised Funds after Changing Sponsor Institution

Notice on Convening the 1st Extraordinary General Meeting in 2026

Announcement on Voluntary Disclosure of Receipt of Approval Notice for the Listing Application of Darunavir Active Pharmaceutical Ingredient

Announcement on Re-signing Tripartite Agreement on Supervision over Deposit in Special Account of Raised Funds after Changing Sponsor Institution

Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference

Announcement on Progress in Acquisition of Minority Shareholders' Stock Rights of a Holding Subsidiary

Announcement on Resolutions of the 2025 Annual General Meeting

Announcement on Progress in Material Asset Reorganization

Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by ACC085 Injection

Announcement on Remuneration Plan for Directors and Senior Management Members for 2026

Announcement on Cancellation of Special Settlement Accounts for Some Raised Fund Financial Products

Announcement on Voluntary Disclosure of Obtained Patent Certificates in Japan

Announcement on Penalties or Regulatory Measures Imposed by Securities Regulatory Authorities and Stock Exchanges in the Recent Five Years

Announcement on Share Increase Plan of Actual Controller

Announcement on Preliminary Earnings Estimate for 2025

Announcement on Using Temporarily Idle Raised Funds for Cash Management

Announcement on Early Return of Remaining Idle Raised Funds Used to Temporarily Supplement Current Capital

Earnings Preannouncement for 2025

Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by ADC205 Tablets

Indicative Announcement on Disclosure of Plan for Issuing A-Shares to Specific Objects by Summary Procedures in 2026

Announcement on Estimated Amount of Daily Related Party Transactions in 2026

Announcement on the Voluntary Disclosure of Renewal and Inclusion of Two Innovative Anti-HIV Drugs in the National Medical Insurance Catalog

Announcement on Voluntary Disclosure of the Successful Enrollment of the 1st Subject in the Phase III Clinical Trial of ACC017 Tablets

Report for Q3 2025

Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by ADC118 Tablets

Announcement on Voluntary Disclosure of Marketing Authorization Approval Received for Dolutegravir Sodium Active Pharmaceutical Ingredient

Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by ADB116 for Injection

Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025

Notice on Convening the 3rd Extraordinary General Meeting in 2025

Announcement on Retirement and Resignation of Core Technical Personnel

Announcement on Attending Semi-annual Collective Performance Briefing for Innovative Drug Industry on SSE STAR Market 2025

2025 Semi-annual Report

Announcement on Completion of Registration of Initial Grant under 2025 Stock Option Incentive Plan

Announcement on Resolutions of the 5th Meeting of the 3rd Board of Directors

Announcement on Voluntary Disclosure of Obtaining Zanzibar Drug Registration Certificate for Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets

Announcement on Completion of Industrial and Commercial Registration for Company Name Change and Business License Renewal

Self-Inspection Report on Trading of the Company's Stocks by Insiders and Incentive Objects of Stock Option Incentive Plan 2025

Review Opinions of the Remuneration and Appraisal Committee of the Board of Directors and Public Disclosure of the List of Recipients for the Initial Grant under the Company's 2025 Stock Option Incentive Plan